Atherosclerosis
Conditions
Keywords
atherosclerosis, 68Ga-FAPI, PET/MR
Brief summary
A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade type I collagen, potentially thinning the fibrous cap. Thus we speculate that atherosclerotic plaque could be imaged with 68Ga-FAPI PET/MR.
Detailed description
A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade type I collagen, potentially thinning the fibrous cap. Previous ex vivo analysis of human aortic atheromata revealed that FAP was expressed in atherosclerotic plaques, and higher FAP expression was detected in thin fibrous caps than thick caps. Constitutive Fap deletion in atherosclerosis-prone mice models could reduce plaque formation and improve plaque stability with increased fibrous cap thickness. Thus we speculate that atherosclerotic plaque could be imaged with 68Ga-FAPI PET/MR.
Interventions
DRUG68Ga-FAPI
intravenously injected with 68Ga-FAPI
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
68Ga-FAPI PET/MR
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* intracranial or carotid atherosclerosis patients * signed informed consent
Exclusion criteria
* pregnancy, breastfeeding * contradictions of MRI * unstable vital signs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic performance | through study completion, an average of 2 years | Diagnostic performance of 68Ga-FAPI PET/MR for intracranial or carotid atherosclerosis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SUVmax | through study completion, an average of 2 years | The difference of SUVmax between asymptomatic and symptomatic atherosclerotic patients |
| FAPI expression | through study completion, an average of 2 years | The correlation of SUVmax and pathological FAPI expression |
Countries
China
Contacts
Primary ContactLi Huo, M.D.
Outcome results
None listed